The European Society for Blood and Marrow Transplantation group reported that the 5‐year OS and relapse rates were 53.8% and 37.0%, respectively, in patients who underwent allo‐HCT for AML with BCR::ABL1 [8]. The gene discussed is ABL1; the disease is acute myeloid leukemia.